A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) (NCT07231952)
A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients With Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
Who can join: Review the eligibility criteria below.
Location: Dana Farber Cancer Institute (Data Collection and Specimen Analysis) — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Dana Farber Cancer Institute (Data Collection and Specimen Analysis) — Boston, Massachusetts
- Beth Israel Deaconess Medical Center (Data Collection Only) — Boston, Massachusetts
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memoral Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
📞 Contact the Study Coordinator
Phone: (646) 608-3711
Email: Palombam@MSKCC.ORG
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Waldenstrom Macroglobulinemia
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom — Los Angeles, California
- Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia — Boston, Massachusetts
- Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer — Bethesda, Maryland
- A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia — Duarte, California
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia — Calgary, Alberta
- Ibrutinib + Venetoclax in Untreated WM — Boston, Massachusetts
Explore by condition: All Waldenstrom Macroglobulinemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.